Correction To: Sunitinib Administered on 2/1 Schedule in Patients with Metastatic Renal Cell Carcinoma: the RAINBOW Analysis

In the original article, Figures 1 and 2 were interchanged.Figure 2Overall survival. Asterisk denotes one patient in the 4/2→2/1 group and two patients in the 2/1 group were not evaluable for OS.View Large Image Figure ViewerDownload Hi-res image Download (PPT) The correct presentation is given below. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisAnnals of OncologyVol. 26Issue 10PreviewFirst-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC), but it is frequently associated with relevant toxicities and subsequent dose reductions. Alternative schedules, such as 2-week-on treatment and 1-week-off (2/1 schedule), might improve tolerability. We evaluated the safety and outcomes of this schedule in a large multicenter analysis. Full-Text PDF Open Archive